Mammography Radiomics Features at Diagnosis and Progression-free Survival Among Patients with Breast Cancer

Overview

Journal Br J Cancer

Specialty Oncology

Date 2022 Sep 1

PMID 36050449

Authors

Chuanxu Luo

Shuang Zhao

Cheng Peng

Chengshi Wang

Kejia Hu

Xiaorong Zhong

Ting Luo

Juan Huang

Donghao Lu

Affiliations

Soon will be listed here.

Abstract

Background: The associations between mammographic radiomics and breast cancer clinical endpoints are unclear. We aimed to identify mammographic radiomics features associated with breast cancer prognosis.

Methods: Nested from a large breast cancer cohort in our institution, we conducted an extreme case-control study consisting of 207 cases with any invasive disease-free survival (iDFS) endpoint <5 years and 207 molecular subtype-matched controls with >5-year iDFS. A total of 632 radiomics features in craniocaudal (CC) and mediolateral oblique (MLO) views were extracted from pre-treatment mammography. Logistic regression was used to identify iDFS-associated features with multiple testing corrections (Benjamini-Hochberg method). In a subsample with RNA-seq data (n = 96), gene set enrichment analysis was employed to identify pathways associated with lead features.

Results: We identified 15 iDFS-associated features from CC-view yet none from MLO-view. S(1,-1)SumAverg and WavEnLL_s-6 were the lead ones and associated with favourable (OR 0.64, 95% CI 0.42-0.87, P = 0.01) and poor iDFS (OR 1.53, 95% CI 1.31-1.76, P = 0.01), respectively. Both features were associated with eight pathways (primarily involving cell cycle regulation) in tumour but not adjacent normal tissues.

Conclusion: Our findings suggest mammographic radiomics features are associated with breast cancer iDFS, potentially through pathways involving cell cycle regulation.

Citing Articles

How Artificial Intelligence Is Shaping Medical Imaging Technology: A Survey of Innovations and Applications.

Pinto-Coelho L Bioengineering (Basel). 2023; 10(12).

PMID: 38136026 PMC: 10740686. DOI: 10.3390/bioengineering10121435.

Estrogen alleviates acute and chronic itch in mice.

Jin J, Li L, Wang Y, Li K, Qian A, Li W Exp Ther Med. 2023; 25(6):255.

PMID: 37153887 PMC: 10155243. DOI: 10.3892/etm.2023.11954.

References

Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M . A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004; 351(27):2817-26. DOI: 10.1056/NEJMoa041588. View

van Timmeren J, Cester D, Tanadini-Lang S, Alkadhi H, Baessler B . Radiomics in medical imaging-"how-to" guide and critical reflection. Insights Imaging. 2020; 11(1):91. PMC: 7423816. DOI: 10.1186/s13244-020-00887-2. View

. Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials. Lancet Oncol. 2021; 22(8):1139-1150. PMC: 8324484. DOI: 10.1016/S1470-2045(21)00288-6. View

Gupta S, Markey M . Correspondence in texture features between two mammographic views. Med Phys. 2005; 32(6):1598-606. DOI: 10.1118/1.1915013. View

Asano Y, Takeuchi T, Okubo H, Saigo C, Kito Y, Iwata Y . Nuclear localization of LDL receptor-related protein 1B in mammary gland carcinogenesis. J Mol Med (Berl). 2019; 97(2):257-268. DOI: 10.1007/s00109-018-01732-2. View

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

Xie Y, Valdimarsdottir U, Wang C, Zhong X, Gou Q, Zheng H . Public health insurance and cancer-specific mortality risk among patients with breast cancer: A prospective cohort study in China. Int J Cancer. 2020; 148(1):28-37. DOI: 10.1002/ijc.33183. View

Salim A, Ma X, Fall K, Andren O, Reilly M . Analysis of incidence and prognosis from 'extreme' case-control designs. Stat Med. 2014; 33(30):5388-98. DOI: 10.1002/sim.6245. View

Mao N, Yin P, Wang Q, Liu M, Dong J, Zhang X . Added Value of Radiomics on Mammography for Breast Cancer Diagnosis: A Feasibility Study. J Am Coll Radiol. 2018; 16(4 Pt A):485-491. DOI: 10.1016/j.jacr.2018.09.041. View

10.

Stelzer P, Steding O, Raudner M, Euller G, Clauser P, Baltzer P . Combined texture analysis and machine learning in suspicious calcifications detected by mammography: Potential to avoid unnecessary stereotactical biopsies. Eur J Radiol. 2020; 132:109309. DOI: 10.1016/j.ejrad.2020.109309. View

11.

Li H, Zhu Y, Burnside E, Drukker K, Hoadley K, Fan C . MR Imaging Radiomics Signatures for Predicting the Risk of Breast Cancer Recurrence as Given by Research Versions of MammaPrint, Oncotype DX, and PAM50 Gene Assays. Radiology. 2016; 281(2):382-391. PMC: 5069147. DOI: 10.1148/radiol.2016152110. View

12.

Brentnall A, Cuzick J, Buist D, Aiello Bowles E . Long-term Accuracy of Breast Cancer Risk Assessment Combining Classic Risk Factors and Breast Density. JAMA Oncol. 2018; 4(9):e180174. PMC: 6143016. DOI: 10.1001/jamaoncol.2018.0174. View

13.

BLOOM H, Richardson W . Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer. 1957; 11(3):359-77. PMC: 2073885. DOI: 10.1038/bjc.1957.43. View

14.

Lambin P, Leijenaar R, Deist T, Peerlings J, de Jong E, van Timmeren J . Radiomics: the bridge between medical imaging and personalized medicine. Nat Rev Clin Oncol. 2017; 14(12):749-762. DOI: 10.1038/nrclinonc.2017.141. View

15.

Gourgou-Bourgade S, Cameron D, Poortmans P, Asselain B, Azria D, Cardoso F . Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials). Ann Oncol. 2015; 26(12):2505-6. DOI: 10.1093/annonc/mdv478. View

16.

Braman N, Etesami M, Prasanna P, Dubchuk C, Gilmore H, Tiwari P . Intratumoral and peritumoral radiomics for the pretreatment prediction of pathological complete response to neoadjuvant chemotherapy based on breast DCE-MRI. Breast Cancer Res. 2017; 19(1):57. PMC: 5437672. DOI: 10.1186/s13058-017-0846-1. View

17.

Cardoso F, Vant Veer L, Bogaerts J, Slaets L, Viale G, Delaloge S . 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer. N Engl J Med. 2016; 375(8):717-29. DOI: 10.1056/NEJMoa1602253. View

18.

Szczypinski P, Strzelecki M, Materka A, Klepaczko A . MaZda--a software package for image texture analysis. Comput Methods Programs Biomed. 2008; 94(1):66-76. DOI: 10.1016/j.cmpb.2008.08.005. View

19.

Li H, Zhu Y, Burnside E, Huang E, Drukker K, Hoadley K . Quantitative MRI radiomics in the prediction of molecular classifications of breast cancer subtypes in the TCGA/TCIA data set. NPJ Breast Cancer. 2016; 2. PMC: 5108580. DOI: 10.1038/npjbcancer.2016.12. View

20.

Ebright R, Lee S, Wittner B, Niederhoffer K, Nicholson B, Bardia A . Deregulation of ribosomal protein expression and translation promotes breast cancer metastasis. Science. 2020; 367(6485):1468-1473. PMC: 7307008. DOI: 10.1126/science.aay0939. View